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OBJECTIVES We sought to investigate the in vivo mechanical properties of a new self-expanding coronary
stent (RADIUS) and, particularly, the subsequent vessel response over time.
BACKGROUND Preclinical studies have suggested that self-expanding stents may produce less vessel wall
injury at initial deployment, leading to larger follow-up lumens than with balloon-expandable
stents. However, the influence of the chronic stimulus from self-expanding stents on the
vessel wall remains unknown.
METHODS Sixty-two patients were randomly assigned to either the RADIUS self-expanding stent group
(n 5 32) or the Palmaz-Schatz balloon-expandable stent group (n 5 30). Intravascular
ultrasound was performed after stent deployment and at six-month follow-up.
RESULTS At follow-up, the RADIUS stents had increased 23.6% in overall volume, while the
Palmaz-Schatz stents had remained unchanged. Due to the greater mean neointimal area
(3.0 6 1.7 mm2 vs. 1.9 6 1.2 mm2, p 5 0.02) in the RADIUS group, no significant
difference in net late lumen loss was observed between the two groups. On the other hand,
analysis at the peristent margins demonstrated that mean late loss was significantly smaller in
the RADIUS group than it was in the Palmaz-Schatz group (0.1 6 2.1 mm2 vs. 1.9 6 2.4
mm2, p 5 0.02).
CONCLUSIONS Serial volumetric IVUS revealed that the RADIUS stents continued to enlarge during the
follow-up period. In this stent implantation protocol, this expansion was accompanied by a
greater amount of neointima than the Palmaz-Schatz stents, resulting in similar late lumen
loss in both configurations. In the peristent margins, however, late lumen loss was minimized
with the RADIUS stents. (J Am Coll Cardiol 2001;37:1329–34) © 2001 by the American
College of Cardiology
Recent studies have shown that coronary stenting reduces
restenosis compared with balloon angioplasty. However,
restenosis rates of 20% to 30% across a broad range of
lesions continue to represent a significant limitation in
terms of both clinical and cost effectiveness. The mecha-
nisms of coronary restenosis in nonstented vessel segments
involve a combination of neointimal hyperplasia and patho-
logic remodeling with overall vessel contraction (1,2). Scaf-
folding a lesion segment with a rigid metal surface prevents
contraction but is one of the strongest stimuli for neointimal
proliferation (3,4).
Animal studies have suggested that the absolute amount
of neointimal proliferation in an arterial segment is propor-
tional to the amount of injury sustained (5–7). For example,
as a stent is expanded with high pressure, immediate injury
occurs deep in the vessel wall within the stented segment as
well as in the unscaffolded peristent margins. Importantly,
several stent trials, especially those involving brachytherapy,
have drawn new attention to the problem of accelerated
lumen loss at stent margins, which accounts for up to
one-third of target vessel revascularization in patients
treated with balloon-expandable stents (8–10).
The pattern and timing of injury with self-expanding
stents, however, may be different from those with conven-
tional balloon-expandable stents. In theory, the ability of
the self-expanding stent to grow in volume from baseline to
follow-up may allow deployment at lower pressures. Less
initial trauma could result in less marked intimal prolifera-
tion. On the other hand, the chronic stimulus on the wall
from a self-expanding stent may be biologically different
from the acute stimulus from a balloon-expandable stent.
The ASSURE (A Stent vs. Stent Ultrasound Remodeling
Evaluation) intravascular ultrasound (IVUS) study was con-
ducted as a substudy of the SCORES (Stent COmparative
REStenosis) trial—a prospective randomized multicenter
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trial designed to evaluate the safety and efficacy of the
RADIUS self-expanding stent compared with the Palmaz-
Schatz balloon-expandable stent. The purpose of the cur-
rent study was to use serial (postintervention and follow-up)
volumetric IVUS to investigate the in vivo mechanical
properties of this new self-expanding coronary stent and,
particularly, the subsequent vessel response in the entire
lesion segment over the follow-up period.
METHODS
Study patients. From December 16, 1996 to April 8, 1997,
66 patients were enrolled in the ASSURE trial and ran-
domly assigned to receive either a RADIUS stent or a
Palmaz-Schatz stent. Patients were asked to sign an
institution-specific consent form before being entered into
the ASSURE protocol. Inclusion criteria consisted of pa-
tients aged 18 or more years with single de novo or
restenotic native vessel disease less than 30 mm in length
and having a reference vessel between 2.75 mm and
4.25 mm in diameter. Patients were not enrolled if they had
multivessel disease or if aspirin or ticlopidine was contrain-
dicated.
Stent implantation protocol. Patients in both groups re-
ceived 325 mg aspirin every day and 250 mg ticlopidine
twice a day within 24 h before the procedure. At the
beginning of the procedure, 10,000 IU of heparin was
administered and supplemented as needed to maintain an
activated clotting time greater than or equal to 250 s
throughout the procedure.
Palmaz-Schatz stents (15 mm in length) were implanted
according to standard protocols as per institutional practice.
This included 1:1 stent to artery sizing with low-pressure
predilation and high-pressure postdilation deployment
techniques. For RADIUS stents, predilation was performed
with a balloon 0.5 mm smaller than the reference vessel
diameter. Either a 14 or 20 mm length stent was used.
Postdeployment dilation was performed in all cases, with
balloon selection and inflation pressure at the discretion of
the individual operator. All operators were blinded to the
IVUS findings after either Palmaz-Schatz or RADIUS
stent deployment. Ticlopidine was prescribed for 30 days,
and aspirin was continued for one year after stent implan-
tation in all cases.
Quantitative coronary angiography. All cineangiograms
were independently analyzed by the Washington Hospital
Center Angiographic Core Laboratory. Cine frames from
multiple projections were digitized and analyzed using an
automated edge-detection algorithm (CAAS-II, the Neth-
erlands). Image calibration was performed using contrast-
filled catheters as the reference standard.
IVUS imaging protocol. One of two commercially avail-
able systems was used for the IVUS studies. The first
(Boston Scientific Corporation, San Jose, California) con-
sisted of a single-element 30 MHz transducer within a 2.9
French or a 3.2 French imaging sheath. The second system
(Hewlett-Packard, Andover, Minnesota) incorporated a
single-element 30 MHz transducer within a 3.5 French
imaging sheath.
Intravascular ultrasound imaging was performed after
administration of intracoronary nitroglycerin (150 to
200 mg). After stent deployment and at six-month follow-
up, a slow pullback was performed from distal to proximal
reference sites through the target segment. An automated
pullback at a constant speed of 0.5 mm/s was performed in
41 cases (RADIUS: 22, Palmaz-Schatz: 19) after initial
deployment and 47 cases (RADIUS: 24, Palmaz-Schatz:
23) at follow-up. Intravascular ultrasound images were
recorded on half-inch, high resolution S-VHS videotape for
off-line analysis.
Serial two-dimensional IVUS analysis. All ultrasound
images were reviewed by an independent core laboratory at
Stanford University Medical Center. The images were
digitized to perform quantitative analysis with commercially
available planimetry software (TapeMeasure, Indec Sys-
tems, Inc., Mountain View, California). Quantitative pa-
rameters consisted of vessel, lumen and stent cross-sectional
areas. Vessel area was defined as the area within the
media/adventitial border (that is, including lumen, plaque
and media). Plaque area was calculated as vessel area minus
lumen area. Neointimal area was computed as stent area
minus lumen area. Qualitative parameters assessed in the
study included: 1) stent apposition (incomplete apposition
being defined as one or more struts clearly separated from
the vessel wall with evidence of blood speckle behind the
strut) and 2) edge tears (defined as disruptions of plaque
immediately adjacent to the stent margins where the flap could
be clearly differentiated from the underlying plaque). Valida-
tion of quantitative and qualitative assessment by IVUS has
been reported previously (11–14).
Intravascular ultrasound measurements were performed
at the tightest segment within the stent and the proximal
and distal reference segments (defined as the location in the
native vessel with minimum disease within 5 mm of the
proximal and distal stent edges and before the emergence of
any major side branches). In cases in which two stents were
placed, the stents were treated as a single stented segment
for purposes of quantitative analysis (the stents overlapped
in all cases). Late lumen area loss was calculated as the
minimum stent/lumen area after initial deployment minus
the minimum lumen area at follow-up.
Serial volumetric IVUS analysis. To further investigate
the in vivo mechanical behavior of the self-expanding stent
and the vessel response in the entire lesion segment, serial
volumetric analysis was performed immediately after stent
Abbreviations and Acronyms
ASSURE 5 A Stent vs. Stent Ultrasound Remodeling
Evaluation
IVUS 5 intravascular ultrasound
SCORES 5 Stent COmparative REStenosis trial
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deployment and at follow-up within the stent and in the
peristent margins (5 mm distal and proximal to the stent
edge) in those cases in which the same IVUS system
(Boston Scientific Corporation) with an automated pullback
was used. Margins were excluded if complete visualization
of the vessel boundary was not achieved along the entire
peristent margin or if a major side branch emerged from the
margin. Measurements of vessel, lumen and stent areas were
made at 1 mm axial intervals, and vessel, stent, lumen,
plaque and neointimal volumes were calculated using Simp-
son’s rule (10,15,16). For comparison between the two stent
configurations, mean stent, lumen and neointimal areas
were computed as the volume divided by the stent length
because stent lengths varied significantly. Mean late lumen
area loss was defined as mean lumen area immediately after
initial deployment minus mean lumen area at follow-up.
Statistics. Quantitative data are presented as mean value 6
SD, and qualitative data are presented as frequencies.
Statistical analysis was performed with StatView 4.5 soft-
ware (Abacus Concepts, Berkeley, California). Continuous
variables were compared using paired t or unpaired t tests. A
two-way repeated measures one-way analysis of variance was
used to test for group (RADIUS, Palmaz-Schatz) and time
(baseline/follow-up) effect and their interactions. Categorical
variables were compared using chi-square test or Fisher exact
test. Significance was assumed at a value of p ,0.05.
RESULTS
Patient characteristics. Sixty-six patients were enrolled in
the ASSURE trial. Due to incomplete image acquisition or
inadequate image quality, four patients were voided. Thirty-
two patients were randomly assigned to the RADIUS group
and 30 to the Palmaz-Schatz group. The demographic
information for these 62 patients is shown in Table 1. No
significant differences were observed between the two
groups with respect to the baseline characteristics.
Fifty-four patients returned for follow-up IVUS exami-
nation (mean period: 6.8 6 2.0 months). In the 51
(RADIUS: 25, Palmaz-Schatz: 26) patients with interpret-
able follow-up IVUS images, 47 (RADIUS: 24, Palmaz-
Schatz: 23) had an automated pullback at follow-up.
Reasons for failure to perform follow-up IVUS for the
complete initial cohort (n 5 66) were as follows: 1) patient
refusal in six cases (RADIUS: 4, Palmaz-Schatz: 2); 2) acute
myocardial infarction in one (RADIUS); 3) unstable angina
in one (Palmaz-Schatz); 4) near total occlusion in two (RA-
DIUS: 1, Palmaz-Schatz: 1) and 5) lost records in two
(RADIUS: 2).
Procedural and angiographic results. As expected, the
stent length was significantly greater in the RADIUS group
compared with the Palmaz-Schatz group. While the final
balloon sizes were similar in both groups, the maximum
inflation pressure was significantly lower in the RADIUS
group (11.7 6 3.6 atm) than it was in the Palmaz-Schatz
group (15.6 6 2.9 atm). There was no significant difference
in the baseline reference diameter in the two groups
(RADIUS: 3.2 6 0.5 mm, Palmaz-Schatz: 3.1 6 0.6 mm).
Serial two-dimensional IVUS results. Initially, there were
no significant differences between the two groups, including
the average reference lumen area (the average of distal and
proximal reference lumen areas), the minimum stent area
and the incidence of incomplete stent apposition (Table 2).
There was a trend toward a lower incidence of edge tears in
the RADIUS group (6% vs. 23%, p 5 0.06).
At follow-up, there were no significant differences in the
two-dimensional IVUS parameters between the two groups,
including the average reference lumen area, the minimum
lumen area and late lumen area loss.
Table 1. Baseline Clinical and Procedural Characteristics
Characteristics
Balloon-Expandable
(n 5 30)
Self-Expanding
(n 5 32)
p
Value
Age, yr 59 6 13 62 6 10 NS
Male gender, n (%) 24 (80) 25 (78) NS
Previous condition, n (%):
Myocardial infarction 11 (37) 10 (31) NS
Coronary angioplasty 10 (33) 5 (16) NS
Coronary artery bypass 2 (7) 1 (3) NS
Risk factors, n (%):
Currently smoking 11 (37) 9 (28) NS
Family history 10 (33) 13 (41) NS
Hypercholesterolemia 15 (50) 12 (38) NS
Hypertension 11 (37) 16 (50) NS
Diabetes 5 (17) 6 (19) NS
Vessel treated, n (%):
LAD/RCA/LCx 9/11/10 (30/37/33) 15/12/5 (47/38/16) NS
Restenotic lesion, n (%) 4 (13) 2 (6) NS
Number of stents per lesion 1.1 6 0.3 1.1 6 0.4 NS
Mean stent length, mm 16.2 6 3.6 19.3 6 6.2 0.02
Final balloon size, mm 3.4 6 0.4 3.5 6 0.4 NS
Maximum inflation pressure, atm 15.6 6 2.9 11.7 6 3.6 , 0.001
LAD 5 left anterior descending artery; LCx 5 left circumflex artery; RCA 5 right coronary artery.
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Serial volumetric IVUS results. Forty-one cases (RADI-
US: 22, Palmaz-Schatz: 19) with an automated pullback
both initially and at follow-up were entered into serial
volumetric analysis. This subset of patients had comparable
baseline characteristics as the overall enrolled patients with
no significant differences between the two stent groups. The
mean neointimal area at follow-up was significantly greater
in the RADIUS group than it was in the Palmaz-Schatz
group (3.0 6 1.7 mm2 vs. 1.9 6 1.2 mm2, p 5 0.02, Figure
1). For stent volume, the time effect of the RADIUS and
Palmaz-Schatz groups showed significant differences, com-
paring baseline and follow-up (p , 0.0001). Between the
two stent groups, there was a significant interaction effect
(p , 0.0001) indicating that the patterns of changes in stent
volume over time differed by the stent types. The RADIUS
stents increased 23.6% in overall stent volume (140.0 6 43.3
mm3 to 173.1 6 47.3 mm3, p , 0.001) or mean stent area
(7.8 6 1.9 mm2 to 9.8 6 2.1 mm2, p , 0.001) (Fig. 1 and
2) between initial deployment and follow-up observation
while the Palmaz-Schatz stents showed no significant
changes in overall stent volume (140.4 6 49.3 mm3 to
136.8 6 45.3 mm3, p 5 0.17) or mean stent area (8.7 6
2.2 mm2 to 8.5 6 2.2 mm2, p 5 0.23). As a result, mean late
lumen area loss trended smaller in the RADIUS group
(1.1 6 2.0 mm2 vs. 2.1 6 1.3 mm2), but this difference did
not reach statistical significance (p 5 0.09).
Peristent margins. Twenty-one margins (distal: 10, prox-
imal: 11) from 16 patients for the RADIUS group and 16
margins (distal: 9, proximal: 7) from 11 patients for the
Palmaz-Schatz group were acceptable for serial volumetric
analysis. During the follow-up period, the increase in mean
plaque area in the peristent margins was similar in the two
stent groups (0.7 6 1.3 mm2 vs. 0.9 6 1.3 mm2, p 5 0.71)
(Table 3, Fig. 3). For vessel volume or mean vessel area,
significant stent type-by-time interaction was observed (p ,
0.01). Vessel volume or mean vessel area in the peristent
margins tended to increase in the RADIUS group (0.8 6
2.4 mm2, p 5 0.13) but was significantly decreased in the
Palmaz-Schatz group (21.1 6 1.8 mm2, p 5 0.03) Con-
sequently, mean lumen area in the peristent margins did not
change significantly in the RADIUS group but decreased
significantly in the Palmaz-Schatz group; mean late lumen
area loss was significantly smaller in the RADIUS group
compared with the Palmaz-Schatz group (0.1 6 2.1 mm2
vs. 1.9 6 2.4 mm2, p 5 0.02).
DISCUSSION
This is the first report comparing the RADIUS stent to the
Palmaz-Schatz stent by serial IVUS examination in a
clinical setting. The major findings of this study were as
follows: 1) the RADIUS stent achieved the same acute
minimum stent area as the Palmaz-Schatz stent using lower
maximum inflation pressures, with a trend toward lower
incidence of edge tears; 2) the RADIUS stent increased
Table 2. Serial Two-dimensional Ultrasound Results
Balloon-
Expandable
Self-
Expanding
p
Value
Initial (after stenting) (n 5 30) (n 5 32)
Avg. reference, area, mm2 8.3 6 3.2 8.5 6 2.5 NS
Minimum stent area, mm2 6.8 6 2.0 6.4 6 2.0 NS
Incomplete apposition, n (%) 5 (17%) 5 (16%) NS
Edge tears, n (%) 7 (23%) 2 (6%) 0.06
Follow-up (n 5 26) (n 5 25)
Avg. reference area, mm2 8.0 6 2.9 8.1 6 3.2 NS
Minimum lumen area, mm2 4.5 6 1.6 4.6 6 2.2 NS
Late lumen area loss, mm2 2.7 6 2.0 2.0 6 1.8 NS
Avg. 5 average.
Figure 1. Mean stent, neointimal and lumen area changes within the
stented segment during the follow-up period. Notably, the RADIUS stents
increased by 1.9 6 1.0 mm2 in mean stent area while the Palmaz-Schatz
stents showed no significant changes. On the other hand, the RADIUS
stents had a greater amount of neointimal proliferation than the Palmaz-
Schatz stents. Values are expressed as mean 6 SD. Open box 5
Palmaz-Schatz; solid box 5 RADIUS.
Figure 2. Changes in stent volume between initial deployment and
follow-up in the Palmaz-Schatz group and the RADIUS group. The
Palmaz-Schatz stents did not change significantly. The RADIUS stents,
however, increased an average of 23.6% in volume (*p , 0.001 vs. initial).
Vertical bars are mean 6 SD. p , 0.001 for the stent type-by-time
interaction.
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23.6% in overall volume by six-month follow-up; 3) the
RADIUS stent had a greater amount of intimal prolifera-
tion than the Palmaz-Schatz stent; 4) the net effect was
similar late loss of lumen area in the stented segment
between the two groups at follow-up; and 5) late lumen loss
in the peristent margins was smaller in the RADIUS group
than it was in the Palmaz-Schatz group.
Chronic injury. The stimulus on the vessel wall from
self-expanding nitinol stent implantation is theoretically
different from the stimulus provoked by balloon-expandable
stents. Several animal studies have provided a histological
framework assessing the vessel response to chronic deep
vessel wall injury caused by self-expanding stents. However,
interpretations vary as to whether gradual stent expansion is
associated with an increase in subsequent neointimal pro-
liferation (17–20). Some animal models with different types
of self-expanding stents have shown that these stents
provoked cellular proliferation that reached its maximum in
three to six months, compared with the earlier peak at one
to three months in the balloon-expandable stent (18,21).
These animal studies indicate that gradual stent expansion
may prolong neointimal proliferation to a variable degree
even beyond three months. On the other hand, there have
been several animal studies (18–20) that indicated no
difference with respect to neointimal proliferation between
the two stent types over time.
The clinical data from the ASSURE trial demonstrate
that chronic expansile force does, in fact, promote a greater
amount of neointimal proliferation in the RADIUS stents.
One potential explanation for this difference in the animal
and clinical data is that the amount, type and distribution of
underlying plaque burden before stent placement can mark-
edly alter the amount of subsequent neointimal prolifera-
tion. Several studies have shown that plaque burden alone
constitutes a strong predictor for restenosis (22,23). More-
over, recent studies have revealed that the plaque burden
behind the stent is strongly correlated with the pattern of
neointimal development (24–26). It is, therefore, reasonable
to assume that chronic expansile force and the underlying
plaque burden may interact in determining the degree of
intimal proliferation. Chronic dilation of a large plaque
burden might be a strong stimulus for intimal growth
although this potential effect did not translate into clinical
disadvantage in this study because of the offset by continued
stent expansion. Considering these properties of self-
expanding stents, unnecessary postdeployment dilation with
high pressures should be avoided in order to minimize vessel
wall injury and subsequent neointimal proliferation. Further
investigation will be needed to determine the appropriate
vessel or lesion subset as well as optimal implantation
technique for this particular type of stents.
Late lumen loss in peristent margins. Recently, several
stent trials with balloon-expandable stents have focused
attention on the accelerated restenosis observed at the stent
margins. These sites have an abrupt transition between the
rigid metal edge of the stent and the adjacent, more
compliant vessel wall. Because the balloon length often
exceeds the stent edge, injury with high-pressure inflations
can occur in the peristent margins several millimeters
proximal and distal to the stent edges. In ASSURE, late loss
in the peristent margins of the Palmaz-Schatz stent resulted
from a combination of neointimal proliferation and vessel
contraction, which is consistent with previous studies
(10,27). In contrast, the gradually expanding stent edge of
the RADIUS stent minimized vessel contraction at the
margins, leading to less net lumen loss at six-month
follow-up.
Table 3. Serial Volumetric Ultrasound Results in the
Peristent Margins
Balloon-expandable
(n 5 16)
Self-expanding
(n 5 21)
p
Value
Vessel volume, mm3
Initial 89.6 6 34.7 76.2 6 28.3 NS
Follow-up 83.9 6 31.4* 80.3 6 33.8 NS
Intimal plaque
volume, mm3
Initial 41.6 6 20.0 33.5 6 18.4 NS
Follow-up 45.3 6 23.9† 38.0 6 20.0‡ NS
DPlaque volume, mm3 3.7 6 6.6 4.5 6 6.5 NS
Lumen volume, mm3
Initial 48.0 6 22.8 42.7 6 14.8 NS
Follow-up 38.7 6 18.6§ 42.3 6 21.1 NS
Late lumen volume
loss, mm3
9.3 6 12.1 0.4 6 10.6 0.02
Mean lumen area, mm2
Initial 9.6 6 4.6 8.5 6 3.0 NS
Follow-up 7.7 6 3.7\ 8.5 6 4.2 NS
Mean late lumen
area loss, mm2
1.9 6 2.4 0.1 6 2.1 0.02
*p 5 0.03; †p 5 0.04; ‡p 5 0.004; §p 5 0.02 vs. initial volumes; \p 5 0.008 vs. initial
mean lumen area.
Figure 3. Mean vessel, plaque and lumen area changes in the peristent
margins (adjacent reference segments) during the follow-up period. The
RADIUS stents minimized vessel contraction resulting in significantly less
net late lumen loss compared with the Palmaz-Schatz stents (0.1 6 2.1
mm2 vs. 1.9 6 2.4 mm2, p 5 0.02). Open box 5 Palmaz-Schatz; solid
box 5 RADIUS.
1333JACC Vol. 37, No. 5, 2001 Kobayashi et al.
April 2001:1329–34 Final Results of the ASSURE Trial
Study limitations. Several significant issues should be
noted. First, the sample size is relatively small, which
limited our ability to determine significance. However, the
SCORES trial consisting of 1,096 patients showed similar
results with respect to the late loss assessed by angiography.
Second, due to the need to pass the IVUS catheter through
the lesion site in order to observe measurement data, only
cases with sufficient lumens to allow for catheter passage can
be analyzed. This might create a study bias toward patients
with larger lumens at follow-up. Third, long-term observa-
tions beyond six months are lacking. However, according to
nonradiation studies with other self-expanding stents and
balloon-expandable stents, neointimal proliferation peaks by
six months without further progression (20,21,28). Fourth,
volumetric measurements in the peristent margins were
limited to the segments in which the vessel boundary could
be clearly visualized throughout the length. Thus, the
current results may not be applicable to severely fibrotic or
calcified lesions. Finally, there remains a possibility that
nitinol itself might have been responsible for the greater
neointimal formation in the RADIUS group. Recently,
hypersensitivity to stent materials has been proposed as a
possible risk factor for stimulation of neointimal hyperpla-
sia. In the general population, however, titanium hypersen-
sitivity is not as common as nickel or stainless steel allergy.
Conclusions. RADIUS stents achieved comparable initial
minimum stent area as Palmaz-Schatz stents at lower
deployment pressures, with a trend toward less stent edge
injury patterns. At follow-up, unlike the Palmaz-Schatz
stent, the overall vessel volume within the RADIUS stent
was significantly increased. However, greater neointimal
proliferation was observed within the RADIUS stent. These
observed differences resulted in similar net late lumen loss
for both stent groups. The margins of the RADIUS stent,
however, showed significantly less late lumen loss than the
margins of the Palmaz-Schatz stent.
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